Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-08-09, Stock:NVS, The news for the past five days is as follows:
2018-08-02: NEWS1: Healthcare Bulls Get a Second Dose of Earnings-Driven Profits.NEWS2: Conatus' (CNAT) Q2 Loss Narrows, Revenues Lag Marginally.NEWS3: Conatus' (CNAT) Q2 Loss Narrows, Revenues Lag Marginally.NEWS4: Conatus&apos; (CNAT) Q2 Loss Narrows, Revenues Lag Marginally.NEWS5: Merck’s Keytruda Witnessed Solid Growth in First Half of 2018.NEWS6: Promacta, Tafinlar + Mekinist, Jakavi: NVS’s Oncology Portfolio.NEWS7: The Swiss Stock Market Dipped On Trade Worries.NEWS8: The Swiss Stock Market Dipped On Trade Worries.NEWS9: How Is Merck’s Diabetes and Women’s Health Business Positioned?.NEWS10: Novartis Is Focused on Advancing Its Oncology Portfolio in 2018.
2018-08-03: NEWS1: Avoid Treating Biogen Like a Speculative Drug Stock.NEWS2: Avoid Treating Biogen Like a Speculative Drug Stock.NEWS3: Teva Chief Says Generic Prices Are Improving — Will Its Stock Also Do So?.NEWS4: bluebird (BLUE) Q2 Loss Wider Than Expected, Revenues Miss.NEWS5: bluebird (BLUE) Q2 Loss Wider Than Expected, Revenues Miss.NEWS6: Avoid Treating Biogen Like a Speculative Drug Stock.NEWS7: Aduro (ADRO) Q2 Loss Narrower Than Expected, Revenues Miss.NEWS8: Aduro (ADRO) Q2 Loss Narrower Than Expected, Revenues Miss.NEWS9: Teva (TEVA) Q2 Earnings Beat, Revenues Miss, Stock Down.NEWS10: Teva (TEVA) Q2 Earnings Beat, Revenues Miss, Stock Down.NEWS11: Pharma Stock Roundup: PFE Dominates Headlines, BMY Drug Gets EU Approval.NEWS12: Pharma Stock Roundup: PFE Dominates Headlines, BMY Drug Gets EU Approval.NEWS13: Aduro (ADRO) Q2 Loss Narrower Than Expected, Revenues Miss.NEWS14: The Swiss Stock Market Finished With A Slight Increase.NEWS15: The Swiss Stock Market Finished With A Slight Increase.NEWS16: Eli Lilly’s Q2 2018 Earnings: New Products.
2018-08-06: NEWS1: Can Mylan Exceed Analysts’ Earnings Estimates in Q2 2018?.NEWS2: Can These Biotech Companies Catch Novartis, Gilead In CAR-T?.NEWS3: Does Bausch Face A Reckoning? 5 Key Issues To Look For In Its Earnings.NEWS4: Could Mylan Again Report a Sales Decline in Q2 2018?.NEWS5: What Analysts Recommend for Mylan before Q2 2018 Earnings.NEWS6: The Zacks Analyst Blog Highlights: Pfizer, Bristol-Myers, Sanofi, Glaxo and Novartis.NEWS7: The Zacks Analyst Blog Highlights: Pfizer, Bristol-Myers, Sanofi, Glaxo and Novartis.NEWS8: Why Novartis Stock Gained 11% in July.NEWS9: Why Novartis Stock Gained 11% in July.NEWS10: The Zacks Analyst Blog Highlights: Pfizer, Bristol-Myers, Sanofi, Glaxo and Novartis.NEWS11: Why Novartis Stock Gained 11% in July.NEWS12: The Swiss Stock Market Dipped In Directionless Trade.NEWS13: The Swiss Stock Market Dipped In Directionless Trade.
2018-08-07: NEWS1: This Midcap Biotech Popped Nearly 20% On Hope In Cancer, Inflammation.NEWS2: Examining Pfizer’s Performance by Segment in Q2 2018.NEWS3: Ligand (LGND) Beats on Q2 Earnings & Revenues, Raises View.NEWS4: Ligand (LGND) Beats on Q2 Earnings & Revenues, Raises View.NEWS5: Teva’s Granix Gets FDA Approval for Expanded Indication.NEWS6: The Swiss Stock Market Climbed As Trade Concerns Relax.NEWS7: The Swiss Stock Market Climbed As Trade Concerns Relax.NEWS8: Mylan Stock Trending Higher before Its Q2 2018 Results.
2018-08-08: NEWS1: 3 Unloved High-Yielders That Will Rise With Rates (and Pay Up to 7% in Cash!).NEWS2: 3 Unloved High-Yielders That Will Rise With Rates (and Pay Up to 7% in Cash!).NEWS3: How Jazz Pharmaceuticals’ Products Performed in the Second Quarter.NEWS4: New Novan incentive plan targets share price goals and $25M, $50M bonus pools.NEWS5: These Products Contributed to Pfizer’s Growth in Q2 2018.NEWS6: Novan Provides Business Update via 10-Q, Adopts Incentive Plan and Agrees to CEO Contract.NEWS7: The Swiss Stock Market Pulled Back On Roche Weakness.NEWS8: The Swiss Stock Market Pulled Back On Roche Weakness.

Answer: Decrease